| 7.43 0.2 (2.77%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.88 | 1-year : | 11.54 |
| Resists | First : | 8.46 | Second : | 9.88 |
| Pivot price | 7.48 |
|||
| Supports | First : | 6.78 | Second : | 5.75 |
| MAs | MA(5) : | 7.19 |
MA(20) : | 7.39 |
| MA(100) : | 8.04 |
MA(250) : | 9.92 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.7 |
D(3) : | 26.9 |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 18.14 | Low : | 5.75 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NPCE ] has closed above bottom band by 46.3%. Bollinger Bands are 42.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.77 - 7.8 | 7.8 - 7.82 |
| Low: | 7.18 - 7.21 | 7.21 - 7.24 |
| Close: | 7.38 - 7.42 | 7.42 - 7.47 |
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Wed, 11 Sep 2024
NeuroPace, Inc. (NASDAQ:NPCE) Receives $14.00 Consensus Target Price from Analysts - MarketBeat
Wed, 11 Sep 2024
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Sat, 31 Aug 2024
NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Financial Advocates Investment Management - Defense World
Thu, 22 Aug 2024
NeuroPace to Participate in Upcoming Healthcare Conferences in September - StockTitan
Tue, 20 Aug 2024
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up - Yahoo Finance
Sun, 18 Aug 2024
NeuroPace (NASDAQ:NPCE) Price Target Cut to $15.00 by Analysts at Wells Fargo & Company - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 29 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 4.1 (%) |
| Held by Institutions | 83.8 (%) |
| Shares Short | 518 (K) |
| Shares Short P.Month | 478 (K) |
| EPS | -1.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -41.7 % |
| Operating Margin | -32.4 % |
| Return on Assets (ttm) | -15.8 % |
| Return on Equity (ttm) | -192.2 % |
| Qtrly Rev. Growth | 16.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.45 |
| EBITDA (p.s.) | -0.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -6.88 |
| PEG Ratio | 0 |
| Price to Book value | 21.85 |
| Price to Sales | 3.02 |
| Price to Cash Flow | -12.71 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|